Oracle Corp. Stock Rises 3.9%, Outperforms Peers
Dow Jones2026/09/29 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Oracle Corp. rose 3.9% to $137.79 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.2% to 7,670.84 and Dow Jones Industrial Average falling 0.3% to 51,349.92.
The stock's rise snapped a four-day losing streak.
Oracle Corp. closed 57.3% short of its 52-week high of $322.54, which the company reached on October 16th.
The stock outperformed some of its peers, as Microsoft Corp. fell 0.1% to $508.96, Alphabet Inc. Cl C fell 0.5% to $337.32, and Alphabet Inc. Cl A fell 0.53% to $340.92.
Trading volume totaled 45.3 million, compared to the 50-day average of 30.5 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 29, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
